An emerging role for Serine Protease Inhibitors in T lymphocyte immunity and beyond

Immunology Letters

Volumn 152, Issue 1, 2013, Pages 65-76

  Ashton Rickardt, Philip G ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Apoptosis; Cytotoxic lymphocytes; Serine Protease Inhibitor; T lymphocytes

Indexed keywords

CATHEPSIN B; CATHEPSIN H; CATHEPSIN K; CATHEPSIN L; CATHEPSIN V; CYTOKINE RESPONSE MODIFIER A; DNA VACCINE; ERYTHROPOIETIN; GAMMA INTERFERON; GRANZYME A; GRANZYME B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 4; LEUKOCYSTATIN; RECOMBINANT PROTEIN; RECOMBINANT SERINE PROTEASE INHIBITOR 6; RECOMBINANT SERINE PROTEASE INHIBITOR B9; SERINE PROTEASE INHIBITOR 2A; SERINE PROTEASE INHIBITOR 6; SERINE PROTEASE INHIBITOR B3; SERINE PROTEASE INHIBITOR B9; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANEMIA; ANTIGEN RECOGNITION; APOPTOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CELLULAR IMMUNITY; CHRONIC KIDNEY DISEASE; CRMA GENE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA IMMUNIZATION; EFFECTOR CELL; ERYTHROPOIESIS; GENE; GENE EXPRESSION REGULATION; GRB GENE; HEMATOPOIETIC STEM CELL; HUMAN; HYPERTENSION; IMMUNE EVASION; IMMUNOLOGICAL MEMORY; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; MEMORY T LYMPHOCYTE; NATURAL KILLER T CELL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SERPINB3 GENE; SERPINB9 GENE; SPI26 GENE; SPI2A GENE;

ANIMALS; CELL DIFFERENTIATION; HOMEOSTASIS; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; SERINE PROTEINASE INHIBITORS; SERPINS; T-LYMPHOCYTES;

EID: 84877822326     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.04.004     Document Type: Review

References (146)

1. Silverman G.A., Bird P.I., Carrell R.W., Church F.C., Coughlin P.B., Gettins P.G.W., et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. J Biol Chem 2001, 276:33293-33296.
2. Remold-O'Donnell E. The ovalbumin family of serpin proteins. FEBS Lett 1993, 315:105-108.
3. Annand R.R., Dahlen J.R., Sprecher C.A., De Dreu P., Foster D.C., Mankovich J.A., et al. Caspase-1 (interleukin-1 beta-converting enzyme) is inhibited by the human serpin analogue proteinase inhibitor 9. Biochem J 1999, 342(Pt 3):655-665.
4. Komiyama T., Ray C.A., Pickup D.J., Howard A.D., Thornberry N.A., Peterson E.P., et al. Inhibition of interleukin-1 beta converting enzyme by the cowpox virus serpin CrmA. An example of cross-class inhibition. J Biol Chem 1994, 269:19331-19337.
5. Tewari M., Dixit V.M. Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J Biol Chem 1995, 270:3255-3260.
6. Zhou Q., Snipas S., Orth K., Muzio M., Dixit V.M., Salvesen G.S. Target protease specificity of the viral serpin CrmA. Analysis of five caspases. J Biol Chem 1997, 272:7797-7800.
7. Liu N., Raja S.M., Zazzeroni F., Metkar S.S., Shah R., Zhang M., et al. NF-kappaB protects from the lysosomal pathway of cell death. EMBO J 2003, 22:5313-5322.
8. Al-Khunaizi M., Luke C.J., Askew Y.S., Pak S.C., Askew D.J., Cataltepe S., et al. The serpin SQN-5 is a dual mechanistic-class inhibitor of serine and cysteine proteinases. Biochemistry 2002, 41:3189-3199.
9. Schick C., Pemberton P.A., Shi G.P., Kamachi Y., Cataltepe S., Bartuski A.J., et al. Cross-class inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: a kinetic analysis. Biochemistry 1998, 37:5258-5266.
10. Luke C.J., Pak S.C., Askew Y.S., Naviglia T.L., Askew D.J., Nobar S.M.V., et al. An intracellular serpin regulates necrosis by inhibiting the induction and sequelae of lysosomal injury. Cell 2007, 130:1108-1119.
11. Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M., et al. APs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998, 17:2215-2223.
12. Turk V., Bode W. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett 1991, 285:213-219.
13. Leist M., Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001, 2:589-598.
14. Ferri K.F., Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol 2001, 3:E255-E263.
15. Schulze-Osthoff K., Bakker A.C., Vanhaesebroeck B., Beyaert R., Jacob W.A., Fiers W. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation. J Biol Chem 1992, 267:5317-5323.
16. Vercammen D., Beyaert R., Denecker G., Goossens V., Van Loo G., Declercq W., et al. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J Exp Med 1998, 187:1477-1485.
17. Vercammen D., Brouckaert G., Denecker G., Van de Craen M., Declercq W., Fiers W., et al. Dual signaling of the Fas receptor: initiation of both apoptotic and necrotic cell death pathways. J Exp Med 1998, 188:919-930.
18. Ha H.C., Snyder S.H. Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci USA 1999, 96:13978-13982.
19. Tolkovsky A.M., Xue L., Fletcher G.C., Borutaite V. Mitochondrial disappearance from cells: a clue to the role of autophagy in programmed cell death and disease. Biochimie 2002, 84:233-240.
20. Denecker G., Vercammen D., Steemans M., Vanden Berghe T., Brouckaert G., Van Loo G., et al. Death receptor-induced apoptotic and necrotic cell death: differential role of caspases and mitochondria. Cell Death Differ 2001, 8:829-840.
21. Lieberman J. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol 2003, 3:361-370.
22. Jaattela M., Tschopp J. Caspase-independent cell death in T lymphocytes. Nat Immunol 2003, 4:416-423.
23. Chwieralski C.E., Welte T., Buhling F. Cathepsin-regulated apoptosis. Apoptosis 2006, 11:143-149.
24. Guicciardi M.E., Deussing J., Miyoshi H., Bronk S.F., Svingen P.A., Peters C., et al. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest 2000, 106:1127-1137.
25. van Eijk M., de Groot C. Germinal center B cell apoptosis requires both caspase and cathepsin activity. J Immunol 1999, 163:2478-2482.
26. Michallet M.C., Saltel F., Flacher M., Revillard J.P., Genestier L. Cathepsin-dependent apoptosis triggered by supraoptimal activation of T lymphocytes: a possible mechanism of high dose tolerance. J Immunol 2004, 172:5405-5414.
27. Yuan X.M., Li W., Dalen H., Lotem J., Kama R., Sachs, et al. Lysosomal destabilization in p53-induced apoptosis. Proc Natl Acad Sci USA 2002, 99:6286-6291.
28. Roberg K., Ollinger K. Oxidative stress causes relocation of the lysosomal enzyme cathepsin D with ensuing apoptosis in neonatal rat cardiomyocytes. Am J Pathol 1998, 152:1151-1156.
29. Roberg K., Kagedal K., Ollinger K. Microinjection of cathepsin D induces caspase-dependent apoptosis in fibroblasts. Am J Pathol 2002, 161:89-96.
30. Foghsgaard L., Wissing D., Mauch D., Lademann U., Bastholm L., Boes M., et al. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J Cell Biol 2001, 153:999-1009.
31. Katz E., Deehan M.R., Seatter S., Lord C., Sturrock R.D., Harnett M.M. B cell receptor-stimulated mitochondrial phospholipase A2 activation and resultant disruption of mitochondrial membrane potential correlate with the induction of apoptosis in WEHI-231 B cells. J Immunol 2001, 166:137-147.
32. Sun J., Bird C.H., Sutton V., McDonald L., Coughlin P.B., De Jong T.A., et al. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem 1996, 271:27802-27809.
33. Sun J., Ooms L., Bird C.H., Sutton V.R., Trapani J.A., Bird P.I. A new family of 10 murine ovalbumin serpins includes two homologs of proteinase inhibitor 8 and two homologs of the granzyme B inhibitor (proteinase inhibitor 9). J Biol Chem 1997, 272:15434-15441.
34. Liu N., Wang Y., Ashton-Rickardt P.G. Serine protease inhibitor 2A inhibits caspase-independent cell death. FEBS Lett 2004, 569:49-53.
35. Hampson L., Hampson I.N., Babichuk C.K., Cotter L., Bleackley R.C., Dexter T.M., et al. A minimal serpin promoter with high activity in haematopoietic progenitors and activated T cells. Hematol J 2001, 2:150-160.
36. Schwartz R.H. Acquisition of immunologic self-tolerance. Cell 1989, 57:1073-1081.
37. Lo D., Sprent J. Identity of cells that imprint H-2-restricted T-cell specificity in the thymus. Nature 1986, 319:672-675.
38. Kisielow P., Teh H.S., Bluthmann H., von Boehmer H. Positive selection of antigen-specific T cells in thymus by restricting MHC molecules. Nature 1988, 335:730-733.
39. Scott B., Bluthmann H., Teh H.S., von Boehmer H. The generation of mature T cells requires interaction of the alpha beta T-cell receptor with major histocompatibility antigens. Nature 1989, 338:591-593.
40. Teh H.S., Kisielow P., Scott B., Kishi H., Uematsu Y., Bluthmann H., et al. Thymic major histocompatibility complex antigens and the alpha beta T-cell receptor determine the CD4/CD8 phenotype of T cells. Nature 1988, 335:229-233.
41. Zerrahn J., Held W., Raulet D.H. The MHC reactivity of the T cell repertoire prior to positive and negative selection. Cell 1997, 88:627-636.
42. Ashton-Rickardt P.G. A license to remember. Nat Immunol 2004, 5:1097-1098.
43. + T-cell memory by cytokines and costimulators. Immunol Rev 2006, 211:23-38.
44. Russell J.H., Ley T.J. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002, 20:323-370.
45. Lau L.L., Jamieson B.D., Somasundaram T., Ahmed R. Cytotoxic T-cell memory without antigen. Nature 1994, 369:648-652.
46. Murali-Krishna K., Altman J.D., Suresh M., Sourdive D.J., Zajac A.J., Miller J.D., et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998, 8:177-187.
47. Ahmed R., Gray D. Immunological memory and protective immunity: understanding their relation. Science 1996, 272:54-60.
48. + T cell effectors can become memory cells with high efficiency and without further division. Nat Immunol 2001, 2:705-710.
49. Lohning M., Hegazy A.N., Pinschewer D.D., Busse D., Lang K.S., Hofer T., et al. Long-lived virus-reactive memory T cells generated from purified cytokine-secreting T helper type 1 and type 2 effectors. J Exp Med 2008, 205:53-61.
50. Opferman J.T., Ober B.T., Ashton-Rickardt P.G. Linear differentiation of cytotoxic effectors into memory T lymphocytes. Science 1999, 283:1745-1748.
51. Becker T.C., Coley S.M., Wherry E.J., Ahmed R. Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. J Immunol 2005, 174:1269-1273.
52. Cassese G., Parretta E., Pisapia L., Santoni A., Guardiola J., Di Rosa F. Bone marrow CD8 cells down-modulate membrane IL-7Ralpha expression and exhibit increased STAT-5 and p38 MAPK phosphorylation in the organ environment. Blood 2007, 110:1960-1969.
53. + T cells. Immunity 2005, 22:259-270.
54. Hildeman D., Jorgensen T., Kappler J., Marrack P. Apoptosis and the homeostatic control of immune responses. Curr Opin Immunol 2007, 19:516-521.
55. Opferman J.T., Letai A., Beard C., Sorcinelli M.D., Ong C.C., Korsmeyer S.J. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003, 426:671-676.
56. Millard P.J., Henkart M.P., Reynolds C.W., Henkart P.A. Purification and properties of cytoplasmic granules from cytotoxic rat LGL tumors. J Immunol 1984, 132:3197-3204.
57. Podack E.R., Young J.D., Cohn Z.A. Isolation and biochemical and functional characterization of perforin 1 from cytolytic T-cell granules. Proc Natl Acad Sci USA 1985, 82:8629-8633.
58. Kagi D., Ledermann B., Burki K., Seiler P., Odermatt B., Olsen K.J., et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994, 369:31-37.
59. Shi L., Kam C.M., Powers J.C., Aebersold R., Greenberg A.H. Purification of three cytotoxic lymphocyte granule serine proteases that induce apoptosis through distinct substrate and target cell interactions. J Exp Med 1992, 176:1521-1529.
60. Kagi D., Vignaux F., Ledermann B., Burki K., Depraetere V., Nagata S., et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994, 265:528-530.
61. Kupfer A., Singer S.J., Dennert G. On the mechanism of unidirectional killing in mixtures of two cytotoxic T lymphocytes. Unidirectional polarization of cytoplasmic organelles and the membrane-associated cytoskeleton in the effector cell. J Exp Med 1986, 163:489-498.
62. Lyubchenko T.A., Wurth G.A., Zweifach A. Role of calcium influx in cytotoxic T lymphocyte lytic granule exocytosis during target cell killing. Immunity 2001, 15:847-859.
63. Stinchcombe J.C., Bossi G., Booth S., Griffiths G.M. The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity 2001, 15:751-761.
64. Froelich C.J., Orth K., Turbov J., Seth P., Gottlieb R., Babior B., et al. New paradigm for lymphocyte granule-mediated cytotoxicity. J Biol Chem 1996, 271:29073-29079.
65. Trapani J.A., Browne K.A., Smyth M.J., Jans D.A. Localization of granzyme B in the nucleus. A putative role in the mechanism of cytotoxic lymphocyte-mediated apoptosis. J Biol Chem 1996, 271:4127-4133.
66. Odake S., Kam C.M., Narasimhan L., Poe M., Blake J.T., Krahenbuhl O.T., et al. Human and murine cytotoxic T lymphocyte serine proteases: subsite mapping with peptide thioester substrates and inhibition of enzyme activity and cytolysis by isocoumarins. Biochemistry 1991, 30:2217-2227.
67. Spaner D., Raju K., Rudvanyi L., Lin Y., Miller R.G. A role for perforin in activation-induced cell death. J Immunol 1998, 160:2655-2664.
68. + T lymphocytes. Int Immunol 2001, 13:411-419.
69. Spaner D., Raju K., Rabinovich B., Miller R.G. A role for perforin in activation-induced T cell death in vivo: increased expansion of allogeneic perforin-deficient T cells in SCID mice. J Immunol 1999, 162:1192-1199.
70. + T cells by perforin. Eur J Immunol 1999, 29:3262-3272.
71. Matloubian M., Suresh M., Glass A., Galvan M., Chow K., Whitmire J.K., et al. A role for perforin in downregulating T-cell responses during chronic viral infection. J Virol 1999, 73:2527-2536.
72. Badovinac V.P., Tvinnereim A.R., Harty J.T. Regulation of antigen-specific T cell homeostasis by perforin and interferon-γ. Science 2000, 290:1354-1357.
73. + T cell expansion and mortality in vaccinated perforin-deficient mice. Immunity 2003, 18:463-474.
74. Stepp S.E., Porunellor A.M., Bennett M., de Saint Basile G., Kumar V. Perforin: more than just an effector molecule. Immunol Today 2000, 21:254-256.
75. Stepp S.E., Dufourcq-Lagelouse R., Le Deist F., Bhawan S., Certain S., Mathew P.A., et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999, 286:1957-1959.
76. + cytolytic T lymphocytes. Proc Natl Acad Sci USA 1990, 87:9015-9019.
77. + T lymphocytes naturally infected with human T cell lymphotropic virus type I. Immunity 2000, 13:657-664.
78. Huang J.F., Yang Y., Sepulveda H., Shi W., Hwang I., Peterson P.A., et al. TCR-mediated internalization of peptide-MHC complexes acquired by T cells. Science 1999, 286:952-954.
79. Chen L., Woo M., Hakem R., Miller R.G. Perforin-dependent activation-induced cell death acts through caspase 3 but not through caspases 8 or 9. Eur J Immunol 2003, 33:769-778.
80. Isaaz S., Baetz K., Olsen K., Podack E., Griffiths G.M. Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re-filling of the lytic granules and secretion of lytic proteins via a non-granule pathway. Eur J Immunol 1995, 25:1071-1079.
81. Ida H., Nakashima T., Kedersha N.L., Yamasaki S., Huang M., Izumi Y., et al. Granzyme B leakage-induced cell death: a new type of activation-induced natural killer cell death. Eur J Immunol 2003, 33:3284-3292.
82. Hirst C.E., Buzza M.S., Bird C.H., Warren H.S., Cameron P.U., Zhang M., et al. The intracellular granzyme B inhibitor, proteinase inhibitor 9, is up-regulated during accessory cell maturation and effector cell degranulation, and its overexpression enhances CTL potency. J Immunol 2003, 170:805-815.
83. + memory cell homeostasis. J Immunol 2004, 173:3801-3809.
84. Zhang M., Park S.M., Wang Y., Shah R., Liu N., Murmann A.E., et al. Serine protease inhibitor 6 protects cytotoxic T cells from self-inflicted injury by ensuring the integrity of cytotoxic granules. Immunity 2006, 24:451-461.
85. Zhang M., Byrne S., Liu N., Wang Y., Oxenius A., Ashton-Rickardt P.G. Differential survival of cytotoxic T cells and memory cell precursors. J Immunol 2007, 178:3483-3491.
86. + T cell immunity. Nat Immunol 2006, 7:1317-1325.
87. Godfrey D.I., MacDonald H.R., Kronenberg M., Smyth M.J., Van Kaer L. NKT cells: what's in a name?. Nat Rev Immunol 2004, 4:231-237.
88. Bendelac A., Savage P.B., Teyton L. The biology of NKT cells. Annu Rev Immunol 2007, 25:297-336.
89. Ansari A.W., Temblay J.N., Alyahya S.H., Ashton-Rickardt P.G. Serine protease inhibitor 6 protects iNKT cells from self-inflicted damage. J Immunol 2010, 185:877-883.
90. Jacob J., Baltimore D. Modelling T-cell memory by genetic marking of memory T cells in vivo. Nature 1999, 399:593-597.
91. Kaech S.M., Hemby S., Kersh E., Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002, 111:837-851.
92. Liu N., Phillips T., Zhang M., Wang Y., Opferman J.T., Shah R., et al. Serine protease inhibitor 2A is a protective factor for memory T cell development. Nat Immunol 2004, 5:919-926.
93. Forsyth S., Horvath A., Coughlin P. A review and comparison of the murine alpha1-antitrypsin and alpha1-antichymotrypsin multigene clusters with the human clade A serpins. Genomics 2003, 81:336-345.
94. + T lymphocytes. J Immunol 2012, 189:1133-1143.
95. + T cell fates via the graded expression of T-bet transcription factor. Immunity 2007, 27:281-295.
96. + T cells by exogenous cell-associated antigens. Immunity 2002, 17:211-220.
97. Zammit D.J., Cauley L.S., Pham Q.M., Lefrancois L. Dendritic cells maximize the memory CD8 T cell response to infection. Immunity 2005, 22:561-570.
98. + dendritic cells are generally involved in priming CTL immunity to viruses. J Immunol 2004, 172:1996-2000.
99. Heath W.R., Belz G.T., Behrens G.M., Smith C.M., Forehan S.P., Parish I.A., et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004, 199:9-26.
100. Hermans I.F., Ritchie D.S., Yang J., Roberts J.M., Ronchese F.C.D8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol 2000, 164:3095-3101.
101. + T cells in vivo. Proc Natl Acad Sci USA 2006, 103:147-152.
102. Wakim L.M., Waithman J., van Rooijen N., Heath W.R., Carbone F.R. Dendritic cell-induced memory T cell activation in nonlymphoid tissues. Science 2008, 319:198-202.
103. Wong P., Pamer E.G. Feedback regulation of pathogen-specific T cell priming. Immunity 2003, 18:499-511.
104. Medema J.P., de Jong J., Peltenburg L.T., Verdegaal E.M., Gorter A., Bres S.A., et al. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA 2001, 98:11515-11520.
105. Lovo E., Zhang M., Wang L., Ashton-Rickardt P.G. Serine protease inhibitor 6 is required to protect dendritic cells from the kiss of death. J Immunol 2012, 188:1057-1063.
106. Graubert T.A., DiPersio J.F., Russell J.H., Ley T.J. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 1997, 100:904-911.
107. Miura Y., Thoburn C.J., Bright E.C., Hess A.D. Cytolytic effector mechanisms and gene expression in autologous graft-versus-host disease: distinct roles of perforin and Fas ligand. Biol Blood Marrow Transplant 2004, 10:156-170.
108. Goldbach-Mansky R., Suson S., Wesley R., Hack C.E., El-Gabalawy H.S., Tak P.P. Raised granzyme B levels are associated with erosions in patients with early rheumatoid factor positive rheumatoid arthritis. Ann Rheum Dis 2005, 64:715-721.
109. + cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2004, 63:483-488.
110. Choy J.C., Cruz R.P., Kerjner A., Geisbrecht J., Sawchuk T., Fraser S.A., et al. Granzyme B induces endothelial cell apoptosis and contributes to the development of transplant vascular disease. Am J Transplant 2005, 5:494-499.
111. Choy J.C., McDonald P.C., Suarez A.C., Hung V.H., Wilson J.E., McManus B.M., et al. Granzyme B in atherosclerosis and transplant vascular disease: association with cell death and atherosclerotic disease severity. Mod Pathol 2003, 16:460-470.
112. Jenkins D., Seth R., Kummer J.A., Scott B.B., Hawkey C.J., Robins R.A. Differential levels of granzyme B, regulatory cytokines, and apoptosis in Crohn's disease and ulcerative colitis at first presentation. J Pathol 2000, 190:184-189.
113. Bien C.G., Bauer J., Deckwerth T.L., Wiendl H., Deckert M., Wiestler O.D., et al. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis. Ann Neurol 2002, 51:311-318.
114. + T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2005, 52:201-211.
115. Bladergroen B.A., Strik M.C., Wolbink A.M., Wouters D., Broekhuizen R., Kummer J.A., et al. The granzyme B inhibitor proteinase inhibitor 9 (PI9) is expressed by human mast cells. Eur J Immunol 2005, 35:1175-1183.
116. Bladergroen B.A., Strik M.C.M., Bovenschen N., van Berkum O., Scheffer G.L., Meijer C.J.L.M., et al. The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites. J Immunol 2001, 166:3218-3225.
117. Young J.L., Sukhova G.K., Foster D., Kisiel W., Libby P., Schonbeck U. The serpin proteinase inhibitor 9 is an endogenous inhibitor of interleukin 1 beta-converting enzyme (caspase-1) activity in human vascular smooth muscle cells. J Exp Med 2000, 191:1535-1544.
118. Quan L., Caputo A., Bleackley R., Pickup D.J., Salvesen G.S. Granzyme B is inhibited by the cowpox virus serpin cytokine response modifier A. J Biol Chem 1995, 270:3-8.
119. Macen J.L., Garner R.S., Musy P.Y., Brooks M.A., Turner P.C., Moyer R.W., et al. Differential inhibition of the Fas- and granule-mediated cytolysis pathways by the orthopoxvirus cytokine response modifier A/SPI-2 and SPI-1 protein. Proc Natl Acad Sci USA 1996, 93:9108-9113.
120. Bladergroen B.A., Meijer C.J., ten Berge R.L., Hack C.E., Muris J.J., Dukers D.F.C., et al. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?. Blood 2002, 99:232-237.
121. ten Berge R.L., Meijer C.J., Dukers D.F., Kummer J.A., Bladergroen B.A., Vos W., et al. Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 2002, 99:4540-4546.
122. Fisher J.W., Koury S., Ducey T., Mendel S. Erythropoietin production by interstitial cells of hypoxic monkey kidneys. Br J Haematol 1996, 95:27-32.
123. Wojchowski D.M., Sathyanarayana P., Dev A. Erythropoietin receptor response circuits. Curr Opin Hematol 2010, 17:169-176.
124. Wu H., Liu X., Jaenisch R., Lodish H.F. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995, 83:59-67.
125. Dev A., Byrne S.M., Verma R., Ashton-Rickardt P.G., Wojchowski D.M. Erythropoietin-directed erythropoiesis depends on serpin inhibition of erythroblast lysosomal cathepsins. J Exp Med 2013, 210:225-232.
126. Johansson A.C., Appelqvist H., Nilsson C., Kagedal K., Roberg K., Ollinger K. Regulation of apoptosis-associated lysosomal membrane permeabilization. Apoptosis 2010, 15:527-540.
127. Blomgran R., Zheng L., Stendahl O. Cathepsin-cleaved Bid promotes apoptosis in human neutrophils via oxidative stress-induced lysosomal membrane permeabilization. J Leukoc Biol 2007, 81:1213-1223.
128. Fibach E., Rachmilewitz E.A. The role of antioxidants and iron chelators in the treatment of oxidative stress in thalassemia. Ann N Y Acad Sci 2010, 1202:10-16.
129. Luckey C.J., Bhattacharya D., Goldrath A.W., Weissman I.L., Benoist C., Mathis D. Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. Proc Natl Acad Sci USA 2006, 103:3304-3309.
130. Medema J.P., Schuurhuis D.H., Rea D., van Tongeren J., de Jong J., Bres S.A., et al. Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J Exp Med 2001, 194:657-667.
131. + T-cell responses induced by DNA immunization. J Virol 2000, 74:8286-8291.
132. Rice J., Dossett M.L., Ohlen C., Buchan S.L., Kendall T.J., Dunn S.N., et al. DNA fusion gene vaccination mobilizes effective anti-leukemic cytotoxic T lymphocytes from a tolerized repertoire. Eur J Immunol 2008, 38:2118-2130.
133. + T cell function and memory development. J Immunol 2007, 179:8313-8321.
134. Kim T.W., Hung C.F., Boyd D.A., He L., Lin C.T., Kaiserman D., et al. Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res 2004, 64:400-405.
135. El Haddad N., Heathcote D., Moore R., Yang S., Azzi J., Mfarrej B., et al. Mesenchymal stem cells express serine protease inhibitor to evade the host immune response. Blood 2011, 117:1176-1183.
136. El Haddad N., Moore R., Heathcote D., Mounayar M., Azzi J., Mfarrej B., et al. The novel role of SERPINB9 in cytotoxic protection of human mesenchymal stem cells. J Immunol 2011, 187:2252-2260.
137. Bien C.G., Widman G., Urbach H., Sassen R., Kuczaty S., Wiestler O.D., et al. The natural history of Rasmussen's encephalitis. Brain 2002, 125:1751-1759.
138. Rowshani A.T., Florquin S., Bemelman F., Kummer J.A., Hack C.E., Ten Berge I.J. Hyperexpression of the granzyme B inhibitor PI-9 in human renal allografts: a potential mechanism for stable renal function in patients with subclinical rejection. Kidney Int 2004, 66:1417-1422.
139. Del Vecchio L., Cavalli A., Tucci B., Locatelli F. Chronic kidney disease-associated anemia: new remedies. Curr Opin Investig Drugs 2010, 11:1030-1038.
140. Dicato M., Plawny L. Erythropoietin in cancer patients: pros and cons. Curr Opin Oncol 2010, 22:307-311.
141. Buttle D.J., Murata M., Knight C.G., Barrett A.J. CA074 methyl ester: a proinhibitor for intracellular cathepsin B. Arch Biochem Biophys 1992, 299:377-380.
142. Spivak J.L., Gascon P., Ludwig H. Anemia management in oncology and hematology. Oncologist 2009, 14(Suppl. 1):43-56.
143. Schmid H., Schiffl H. Erythropoiesis stimulating agents and anaemia of end-stage renal disease. Cardiovasc Hematol Agents Med Chem 2010, 8:164-172.
144. Willinger T., Freeman T., Hasegawa H., McMichael A.J., Callan M.F. Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets. J Immunol 2005, 175:5895-5903.
145. Halfon S., Ford J., Foster J., Dowling L., Lucian L., Sterling M., et al. Leukocystatin, a new Class II cystatin expressed selectively by hematopoietic cells. J Biol Chem 1998, 273:16400-16408.
146. Willoughby C.A., Bull H.G., Garcia-Calvo M., Jiang J., Chapman K.T., Thornberry N.A. Discovery of potent, selective human granzyme B inhibitors that inhibit CTL mediated apoptosis. Bioorg Med Chem Lett 2002, 12:2197-2200.